Cellumen says it will use an $8.7 million injection of venture capital to begin its commercialization efforts. The company specializes in cellular systems biology for drug discovery work. Safeguard Scientifics provided $6 million of that while PA Early Stage Partners put up $2 million.
- see the release
- read the the Pittsburgh Business Journal report